Dr. Santomasso on Managing CNS Toxicity from CAR T-Cell Therapy for B-Cell Lymphoma

Video

In Partnership With:

Bianca D. Santomasso, MD, PhD, discusses how she prevents central nervous system toxicity due to CAR T-cell therapy for aggressive B-cell lymphoma in her own practice.

Bianca D. Santomasso, MD, PhD, assistant attending neurologist, Memorial Sloan Kettering Cancer Center, discusses how she prevents central nervous system toxicity due to CAR T-cell therapy for aggressive B-cell lymphoma in her own practice.

Santomasso and her colleagues perform the Immune Effector Cell Encephalopathy (ICE) screening at least once daily on patients who have received CAR T-cell therapy. The perfect score on ICE is 10 and when a patient's score drops to 9, they start to be monitored more closely.

Severe cases of neurotoxicity can progress beyond language and disorientation to seizures and even falling into a coma, explains Santomasso. When patients have severe toxicity, they are given corticosteroids. Santomasso is unsure how the corticosteroids reverse the toxicity, but she believes they prevent the most severe progression as the toxicity runs its course. Some patients spontaneously recover without steroids, but corticosteroids are usually given to be safe. In Santomasso’s experience, giving corticosteroids has not changed the efficacy of treatment, though it is a subject being actively researched.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD